Price$16.85-0.24 (-1.40%)
01:45 PM07:45 PM
News · 26 weeks35-79%
2025-10-262026-04-19
Mix1990d
- Insider10(53%)
- SEC Filings5(26%)
- Earnings2(11%)
- Other2(11%)
Latest news
25 items- SECSEC Form DEFA14A filed by Neuropace Inc.DEFA14A - NeuroPace Inc (0001528287) (Filer)
- SECSEC Form DEF 14A filed by Neuropace Inc.DEF 14A - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focu
- INSIDERSEC Form 4 filed by Morrell Martha4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERSEC Form 4 filed by Geiger Uri4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERSEC Form 4 filed by Lacob Joseph4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERSEC Form 4 filed by Kumar Rakhi4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERSEC Form 4 filed by Fischer Frank M4 - NeuroPace Inc (0001528287) (Issuer)
- PRNeuroPace to Present at the Leerink Global Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused o
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 5,023 shares, decreasing direct ownership by 5% to 96,937 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- SECSEC Form S-8 filed by Neuropace Inc.S-8 - NeuroPace Inc (0001528287) (Filer)
- SECSEC Form 10-K filed by Neuropace Inc.10-K - NeuroPace Inc (0001528287) (Filer)
- SECNeuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NeuroPace Inc (0001528287) (Filer)
- PRNeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook-- Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth -- -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS® revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE) -- -- Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement (PMA-S) approval in mid-2026 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. Fourth Quarter 2025 Financial Highlights To
- INSIDERCHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 101,960 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.48% to 74,964 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 3,412 shares, decreasing direct ownership by 4% to 75,322 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- PRNeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The webcast will be archived on the company's in
- PRNeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook--Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- -- 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy (IGE)-- --IGE is expected following potential approval in the second half of 2026-- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million,
- PRNeuroPace to Present at the 44th Annual J.P. Morgan Healthcare ConferenceNeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device com
- INSIDERDirector Lacob Joseph was granted 678 shares, increasing direct ownership by 5% to 13,889 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Kumar Rakhi was granted 904 shares, increasing direct ownership by 5% to 18,007 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Fischer Frank M was granted 1,431 shares, increasing direct ownership by 0.24% to 593,351 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)
- INSIDERDirector Geiger Uri was granted 715 shares, increasing direct ownership by 5% to 13,945 units (SEC Form 4)4 - NeuroPace Inc (0001528287) (Issuer)